Table 3.
Unadjusted Peak Laboratory Values by Statin Treatment Group (N = 1179)
| Laboratory Value | Peak Value by Statin Treatment Group, Median (IQR)a | P Valueb | |||
|---|---|---|---|---|---|
| Group A: Continued (n=466) | Group B: Discontinued (n=42) | Group C: Newly Initiated (n=311) | Group D: Never (n=360) | ||
| WBC count, cells/µL | 8.7 (6.6–12.5) [n=466] | 7.9 (6.3–16) [n=40] | 9.9 (7.1–15.2) [n=311] | 8.3 (6.2–12.1) [n=349] | .001 |
| AST, U/L | 65 (40–119) [n=463] | 60 (32–208) [n=38] | 84 (45–150) [n=311] | 66 (35–127) [n=338] | .008 |
| ALT, U/L | 46 (26–85) [n=463] | 47 (23–121) [n=38] | 68 (31–120) [n=311] | 57 (26–118) [n=338] | <.001 |
| Total bilirubin, mg/dL | 0.7 (0.5–1.1) [n=463] | 0.5 (0.4–0.8) [n=38] | 0.6 (0.5–1) [n=311] | 0.6 (0.4–0.9) [n=339] | .01 |
| Alkaline phosphatase, U/L | 105 (79–166) [n=463] | 101 (77–155) [n=38] | 97 (72–156) [n=311] | 96 (72–140) [n=338] | .02 |
| Troponin, ng/L | 23 (10–52) [n=451] | 40 (14–90) [n=38] | 12 (6–29) [n=305] | 8 (6–23) [n=322] | <.001 |
| CRP, mg/L | 145 (69–252) [n=459] | 141 (50–231) [n=36] | 151 (82–283) [n=311] | 117 (52–175) [n=330] | <.001 |
| ESR, mm/h | 57 (36–104) [n=426] | 68 (36–90) [n=32] | 72 (41–114) [n=297] | 44 (26–74) [n=295] | <.001 |
| Creatine kinase, U/L | 178 (85–507) [n=461] | 374 (89–838) [n=36] | 222 (90–636) [n=310] | 173 (78–578) [n=331] | .03 |
| D-dimer, ng/mL | 1863 (986–3596) [n=455] | 1944 (1075–7380) [n=37] | 2090 (1038–5098) [n=305] | 1241 (713–3270) [n=329] | <.001 |
| Absolute lymphocyte count, ×103 cells/µL | 1.6 (1.1–2.2) [n=466] | 1.5 (1–2.5) [n=40] | 1.9 (1.4–2.4) [n=311] | 1.7 (1.3–2.3) [n=341] | <.001 |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range; WBC, white blood cell.
Statin treatment groups were defined as follows: group A, antecedent (prehospitalization) statin continued during hospitalization (Continued); group B, antecedent statin discontinued during hospitalization (Discontinued); group C, statin newly initiated during hospitalization (Newly Initiated); and group D, no statins used during or before hospitalization (Never).
P values were calculated comparing all 4 groups, using the Kruskal-Wallis test for continuous variables and Fisher exact test for categorical variables.